Aria Clinic S.R.L.

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Alzheimer disease4 trials
• Multiple sclerosis1 trial
• Myasthenia gravis1 trial

Phase

• Phase 36 trials

Status

• Completed2 trials
• Recruiting2 trials
• Active, not recruiting1 trial
• Not yet recruiting1 trial

Lead sponsor

• Bristol-Myers Squibb2 trials
• Novo Nordisk A/S2 trials
• Immunic AG1 trial
• Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany1 trial

Running trials

• Recruiting

  A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

  NCT06937229· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

  NCT07011732· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

  NCT06463587· Phase 3· Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany· Source

• Active, not recruiting

  Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

  NCT05201638· Phase 3· Immunic AG· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease2 recruiting
• Myasthenia gravis1 recruiting

Closed trials

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

  NCT04777396· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

  NCT04777409· Phase 3· Novo Nordisk A/S· Source